In this webinar, Magdalena Pacewicz will highlight how to use AUC to characterize AAVs as part of ensuring regulatory ...

Adeno-associated virus (AAV) is the most popular vector of choice for gene therapy because of its low immunogenicity and ability to infect numerous cells and tissue types. However, with hundreds of ...

Safe and effective gene therapy strategies depend on robust and reliable adeno-associated virus (AAV) mediated therapeutic gene delivery. However, scaling up AAV manufacturing to obtain sufficient ...

Ajinomoto CELLiST Korea, a subsidiary of the Ajinomoto Group specializing in the development and manufacturing of cell culture media, has launched CELLiSTTM AAV Production Supplement 1, a newly ...

PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...

Researchers from MIT have developed a bioreactor simulator to predict adeno-associated virus (AAV) yields for insect cell/baculovirus manufacturing. Francesco Destro, PhD, a postdoctoral associate ...

Virica Biotech will provide a panel of their cell enhancers for use in high-throughput AAV production screening for Ginkgo’s clients. Ginkgo Bioworks will leverage their advanced screening platform ...

SPRING HOUSE, Pa. and WATERTOWN, Mass., March 17, 2025 /PRNewswire/ -- ChromaTan Inc., and Landmark Bio PBLLC, today announced they have been awarded a grant from the National Institute for Innovation ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Viral vectors are vital for the cell and gene therapy industry. However, long production timelines, combined with quality and consistency issues, mean that growing demand is outstripping supply. The ...

New data from Ascend's R&D team demonstrate up to 3-fold increase in AAV yields, supporting greater efficiency and scalability across gene therapy programs. MUNICH, Nov. 10, 2025 /PRNewswire/ -- ...